Fortress Biotech, Inc. (FBIOP)
| Previous close | 16.00 |
| Open | 16.22 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 15.86 - 16.50 |
| 52-week range | 6.40 - 18.91 |
| Volume | |
| Avg. volume | 12,124 |
| Market cap | 86.315M |
| Beta (5Y monthly) | 1.53 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.86 |
| Earnings date | 13 May 2024 - 17 May 2024 |
| Forward dividend & yield | 2.34 (14.47%) |
| Ex-dividend date | 12 Apr 2024 |
| 1y target est | N/A |
GlobeNewswireJourney Medical Corporation to Announce First Quarter 2024 Financial Results on May 13, 2024
Company to host conference call to discuss financial results and provide a corporate update on May 13, 2024 at 4:30 p.m. ETSCOTTSDALE, Ariz., May 07, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the “Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that focuses on the selling and marketing of FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the Company will release its first quarter
GlobeNewswireMustang Bio Announces Closing of $4 Million Public Offering
Potential Additional Gross Proceeds Upon Cash Exercise of Warrants of Up to $12 MillionWORCESTER, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang” or the “Company”) (Nasdaq: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for difficult-to-treat cancers, today announced the closing of its previously announced public offering for the purchase and sale of an aggregate of 16,877
- GlobeNewswire
Journey Medical Corporation Appoints Joseph Benesch as Chief Financial Officer
SCOTTSDALE, Ariz., May 01, 2024 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced the appointment of Joseph M. Benesch as Chief Financial Officer, effective April 26, 2024. Mr. Benesch had served as t
